Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell LymphomaFrancine M. Foss, Madeleine Duvic, Costas K. Yannakou et al.|Journal of Clinical Oncology|2024Cited by 22
Targeted genomic analysis of cutaneous T cell lymphomas identifies a subset with aggressive clinicopathological featuresKimon V. Argyropoulos, M. Lia Palomba, Melissa Pulitzer et al.|Blood Cancer Journal|2020Cited by 12
Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302H. Miles Prince, Francine M. Foss, Larisa J. Geskin et al.|Blood|2022Cited by 4
High-Depth, Targeted, Next Generation Sequencing Identifies Novel Genetic Alterations in Cutaneous T-Cell LymphomaKimon V. Argyropoulos, Lia Palomba, Sarah McCue Horwitz et al.|Blood|2015Cited by 1